Nurix Therapeutics Profit Margin

The latest profit margin for NRIX is -928.44% as of May 2026. That compares with -234.58% in the prior-year period — down 295.8% year over year. That is below the Healthcare sector average of 13.89%. Investors often review this figure alongside Nurix Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, NRIX's profit margin moved from -234.58% to -928.44% — a 295.8% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Nurix Therapeutics's valuation or profitability profile.

Against Healthcare companies, NRIX currently prints -928.44% for profit margin, while the sector average sits near 13.89%. That is roughly 6782.8% below the sector mean. Large gaps often invite a closer look at Nurix Therapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively Nurix Therapeutics converts resources into returns. At -928.44%, NRIX may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -234.58% in the prior-year period — down 295.8% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting NRIX's profit margin (-928.44%), review year-over-year change from -234.58%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.